The routine use of high-resolution immunological screening of recipients of primary deceased donor kidney allografts is cost-effective

Transplantation

Volumn 81, Issue 9, 2006, Pages 1278-1284

  McLaughlin, Kevin ^a,d   Manns, Braden ^a   Nickerson, Peter ^b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRAFT REJECTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; FLOW CYTOMETRY; GRAFT FAILURE; HEALTH CARE COST; HEMODIALYSIS; HIGH RESOLUTION IMMUNOLOGICAL SCREENING; HIGH RISK PATIENT; HISTOCOMPATIBILITY; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; LIFE EXPECTANCY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SCREENING; SERODIAGNOSIS;

CADAVER; CANADA; COST-BENEFIT ANALYSIS; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC TESTS; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; TISSUE DONORS; TREATMENT OUTCOME;

EID: 33744491807     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000205797.05544.e5     Document Type: Article

References (44)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
2. Goeree R, Manalich J, Grootendorst P, et al. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 1995; 18: 455-464.
3. Laupacis A, Keown P, Pus N, et al. A study ot the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235-242.
4. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis 2002; 40: 611-622.
5. Whiting JF, Kiberd B, Kalo Z, et al. Cost-effectiveness of organ donation: Evaluating investment into donor action and other donor initiatives. Am J Transplant 2004; 4: 569-573.
6. Kaplan B, Meier-Kriesche HU. Death after graft loss: An important late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970-974.
7. Rao PS, Schaubel DE, Saran R. Impact of graft failure on patient survival on dialysis: A comparison of transplant-naive and post-graft failure mortality rates. Nephrol Dial Transplant 2005; 20: 387-391.
8. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
9. Amos DB, Bashir H, Boyle W, et al. Simple micro cytotoxicity test. Transplantation 1969; 7: 220-223.
10. Johnson AH, Rossen RD, Butler WT. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: Identification of low levels of preformed antibodies in accelerated allograft rejection. Tissue Antigens 1972; 2: 215-226.
11. Kerman RH, Kimball PM, Van Buren CT, et al. AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation 1991; 51: 316-320.
12. Gebel H, Bray RA. Sensitization and sensitivity: Defining the unsensitized patient. Transplantation 2000; 69: 1370-1374.
13. Le Bas-Bernardet S, Hourmant M, Valentin N, et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003; 75: 477-482.
14. Iwaki Y, Lau M, Cook DJ, et al. Crossmatching with B and T cells with flow cytometry. Clin Transpl 1986: 277-284.
15. Zachary AA, Ratner LE, Graziani JA, et al. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets. II. Clinical relevance. Hum Immunol 2001; 62: 236-246.
16. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488-1500.
17. McLaughlin K, Manns B, Mortis G, et al. Why patients with end-stage renal disease do not select self-care dialysis as a treatment option. Am J Kidney Dis 2003; 41: 380-385.
18. Manns BJ, Lee H, Doig CJ, et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347: 993-1000.
19. Tonelli M, Winkelmayer WC, Jindal KK, et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003; 64: 295-304.
20. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993; 13: 322-338.
21. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987; 40: 593-600.
22. Bank of Canada financial markets department year average exchange rates. http://www.bankofcanada.ca/en/rates/exchange_avg_pdf.html. 2005.
23. Gold MR, Sieleg JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York, Oxford University Press, 1996.
24. Mahoney RJ, Ault KA, Given SR, et al. The flow cytometric crossmatch and early transplant loss. Transplantation 1990; 49: 527-535.
25. LeFor WM, Ackermann JRW, Alveranga DY, et al. Flow cytometry crossmatching and primary cadaver kidney graft outcome: Relevance of T and B cell targets, historic sera and autologous controls. Clin Transplant 1996; 10: 601-606.
26. Karpinski M, Rush DR, Jeffrey J, et al. Flow cytometric cross-matching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 2807-2814.
27. Iwaki Y, Cook DJ, Terasaki P, et al. Flow cytometry crossmatching in human cadaver kidney transplantation. Transplant Proc 1987; 19: 764-766.
28. Cook DJ, Terasaki PI, Iwaki Y, et al. An approach to reducing early kidney transplant failure by flow cytometry crossmatching. Clin Transplant 1987; 1: 253-256.
29. Ogura K, Terasaki PI, Johnson C. The significance of a positive flow cytometric crossmatch test in primary renal transplantation. Transplantation 1993; 56: 294-298.
30. Pelletier RP, Orosz CG, Adams PW. Clinical and economic impact of flow cytometry crossmatching in primary cadaveric kidney and simultaneous pancreas-kidney transplant recipients. Transplantation 1997; 63: 1639-1645.
31. Kimball P, Rhodes C, King A, et al. Flow cross-matching identifies patients at risk of postoperative elaboration of cytotoxic antibodies. Transplantation 1998; 65: 444-446.
32. Kerman RH, Susskind B, Buyse I, et al. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 1999; 66: 1827-1838.
33. El Fettouh HA, Cook DJ, Bishay E, et al. Association between a positive flow cytometry crossmatch and the development of chronic rejection in primary renal transplantation. Urology 2000; 56: 369-372.
34. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
35. Murphy SW, Foley RN, Barrett BJ, et al. Comparative mortality of hemodialysis and peritoneal dialysis in Canada. Kidney Int 2000; 57: 1720-1726.
36. Rosner B. Study guide for fundamentals of biostatistics. Cambridge, MA, Harvard University, 2000.
37. http://www.oia.ucalgary-ca/cpi/cpifront.htm.
38. Takemoto S, Zeevi A, Feng S, et al. National conference to assess antibody mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041.
39. Canadian Council for Donation and Transplantation. Assessment and management of immunological risk in transplantation: A CCDT consensus forum. 2005.
40. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665-673.
41. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
42. Sonnenday CJ, Ratner LE, Zachary AA, et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002; 34: 1614-1616.
43. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-283.
44. Clark WF, Churchill DN, Forwell L, et al. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ 2000; 162: 195-198.